Tetrabenazine 25 Mg Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER
Tetmodis 25 mg tablets
{Tetrabenazine}
Read all of this leaflet carefully before you start taking this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
In this leaflet:
1. What Tetmodis is and what it is used for
2. Before you take Tetmodis
3. How to take Tetmodis
4. Possible side effects
5. How to store Tetmodis
6. Further information
1. WHAT TETMODIS IS AND WHAT IT IS USED FOR
Tetmodis is a medicine belonging to the group treating disorders of the nervous system.
Tetmodis is used for the treatment of diseases causing jerky, irregular, uncontrollable movements (hyperkinetic motor disorders with Huntington’s chorea).
2. BEFORE YOU TAKE TETMODIS Do not take Tetmodis
- if you are allergic (hypersensitive) to tetrabenazine or any of the other ingredients of Tetmodis 25 mg tablets.
- if you use reserpine (medicine to control high blood pressure and treat psychotic states).
- if you use MAO inhibitors (medicine to treat depression)
- if you suffer from Parkinson-like symptoms
- if you have a depression
- if you are breast-feeding
- if you suffer from pheochromocytoma (tumour of the adrenal gland)
- If you suffer from pro-lactin-dependent tumours, e.g. pituitary or breast cancer
Take special care with Tetmodis
- if you are suffering from mild to severe hepatic impairment
- if you have a heart condition known as long QT syndrome or if you have or have had problems with your heart rhythm.
- if you start to have mental changes such as confusion or hallucinations, or develop stiffness in your muscles and a temperature, you may be developing a condition called Neuroleptic Malignant Syndrome. If you have these symptoms please contact your doctor straight away.
Taking other medicines
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Take special care if you use Tetmodis together with Levodopa (a medicine used to treat Parkinson’s disease). Do not use Tetmodis together with reserpine. Treatment with MAO inhibitors should be stopped 14 days before the treatment with tetrabenazine starts.
It is not recommended to use this medicine with certain types of antidepressants, alcohol,opioids, beta blockers, antihypertensive drugs (medicine to treat high blood pressure), hypnotics and neuroleptics (medicine to treat psychotic disorders).
Inhibitors of CYP2D6 (e.g. fluoxetine, paroxetine, terbinafine, moclobemide and quinidine) may result in increased plasma concentrations of the active metabolite dihydrotetrabenazine, why they should only be combined with caution. A reduction of the tetrabenazine dose may be necessary.
Take special care if you use Tetmodis together with drugs known to prolong the QTc interval in the ECG, including some drug used to treat mental health conditions (neuroleptics), certain antibiotics (e.g. gatifloxacin, moxifloxacin) and some drugs used to treat problems with heart rhythm conditions (e.g. quinidine, procainamide, amiodarone, sotalol).
Pregnancy and breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine. Your doctor will decide after taking all risks and benefits into account, if you may use Tetmodis during pregnancy. Tetmodis must not be taken by breast feeding mothers.
Driving and using machines
Tetmodis may cause drowsiness and therefore may modify your performance at driving and using machines to a varying degree, depending on the dose and individual susceptibility.
Important information about some of the ingredients of Tetmodis
These tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
3. HOW TO TAKE TETMODIS
Always take Tetmodis exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
Adults
Huntington’s chorea
The recommended starting dose is half a tablet (12.5 mg) one to three times a day. This can be increased every three or four days by half a tablet until the optimal effect is observed or up to the occurrence of intolerance effects (sedation, Parkinsonism, depression).
The maximum daily dose is 8 tablets (200 mg) a day.
If you have taken the maximum dose for a period of seven days and your condition has not improved, it is unlikely that the medicinal product will be of benefit to you.
The elderly
The standard dosage has been administered to elderly patients without apparent side effects. However, Parkinson-like side effects are common.
Children
The treatment is not recommended in children.
Patients with hepatic disorder
Patients with mild to moderate hepatic disorders should start with half a tablet a day. For patients with severe hepatic disorders, additional caution is necessary.
Patient with renal disorder
Tetmodis is not recommended for use in this patient group.
Swallow the tablet(s) with water or another non-alcoholic drink.
If you take more Tetmodis than you should
If you take more Tetmodis than you should, you may develop drowsiness, sweating, low blood pressure, and extremely low body temperature (hypothermia). Your doctor will treat the signs.
If you forget to take Tetmodis
If you forget to take one dose, you should never make up for the missing dose by doubling it at the next time. Instead you should simply continue with the next dose when it is due.
If you stop taking Tetmodis
Do not stop taking Tetmodis unless your doctor tells you to. A neuroleptic malignant syndrome has been described after abrupt withdrawal of tetrabenazine.
If you have any further question on the use of this product, ask your doctor or pharmacist.
4. POSSIBLE SIDE EFFECTS
Like all medicines, Tetmodis can cause side effects, although not everybody gets them.
The following undesirable effects are ranked according to system organ class and to their frequency:
very common: affects more than 1 user in 10
common: affects 1 to 10 users in 100
uncommon: affects 1 to 10 users in 1,000
rare: affects 1 to 10 users in 10,000
very rare: affects less than 1 user in 10,000
not known: frequency cannot be estimated from the available data
Very common:
Drowsiness (with higher dosages), depression, Parkinson-like syndrome (uncontrollable movements of the hands, arms, legs and head, with higher dosages)
Common:
Confusion, anxiety, sleeplessness, low blood pressure, dysphagia (difficulty in swallowing), nausea, vomiting, diarrhoea, obstipation
Uncommon:
Mental changes such as confusion or hallucinations, muscular rigidity, fever, autonomic dysfunction Rare:
Neuroleptic malignant syndrome (NMS) (neurological disorder)
Very rare:
Skeletal muscle damage
For the following side-effects, it is not possible to estimate the incidence from available data: Disorientation, nervousness, ataxia, akathisia, dystonia, dizziness, amnesia, bradycardia, epigastric pain, dry mouth
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
5. HOW TO STORE TETMODIS
Keep out of the reach and sight of children.
Do not use Tetmodis after the expiry date which is stated on the bottle and carton. The expiry date refers to the last day of that month.
Store in the original package in order to protect from light.
This medicinal product does not require any special temperature storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
6. FURTHER INFORMATION What Tetmodis contains
- The active substance is tetrabenazine.
- Each tablet contains 25 mg tetrabenazine.
- The other ingredients are: pregelatinised maize starch, lactose monohydrate, talc, iron oxide yellow E172, magnesium stearate.
What Tetmodis looks like and contents of the pack
Yellow, round tablets with one-side break notch and “TE25” engraved on the back side in white twist-off bottles with 112 tablets.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder:
AOP Orphan Pharmaceuticals AG 1160 Vienna, Austria
Manufacturer:
AOP Orphan Pharmaceuticals AG 1160 Vienna, Austria
This medicinal product is authorised in the Member States of the EEA under the following names:
Austria:
Belgium:
Bulgaria:
Czech Republic:
Denmark:
Estonia:
Finland:
France:
Germany:
Greece:
Hungary:
Ireland:
Latvia:
Lithuania:
Netherlands:
Poland:
Portugal:
Tetmodis 25 mg Tabletten
Tetrabenazine AOP Orphan Pharmaceuticals 25 mg tabletten
TETMOfl,HC 25 mg Tadnera
Tetmodis 25 mg tablety
Tetmodis 25 mg tabletter
Tetmodis 25 mg tablett
Tetmodis 25 mg taletti
Comprimes Tetmodis 25 mg
Tetmodis 25 mg Tabletten
Tetmodis 25 mg Sroria
Motetis 25 mg tabletta
Tetmodis 25 mg tablets
Tetmodis 25 mg tabletes
Tetmodis 25 mg tabletes
Tetmodis 25 mg tabletten
Tetmodis 25 mg tabletki
Comprimidos de Tetmodis 25 mg
|
Romania: Slovakia: Slovenia: Spain: Sweden: United Kingdom: |
Tetmodis, tablete, 25 mg Tetmodis 25 mg tableta Tetmodis 25 mg tablete Tetmodis 25 mg comprimidos Tetmodis 25 mg tablett Tetmodis 25 mg tablets |
This leaflet was last approved in 31.01.2015
5